awmsg logo



ponatinib (Iclusig®)


Reference No. 1163

Publication date:
13/01/2015


Appraisal information

ponatinib (Iclusig®) 15 mg film-coated tablet
ponatinib (Iclusig®) 45 mg film-coated tablet


Company: ARIAD Pharma UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 15/10/2014
AWMSG meeting date: 12/11/2014
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 3714
Ministerial ratification: 09/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA451) NICE GUIDANCE ISSUED JUNE 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download